EUCTR2021-000170-29-PL进行中（未招募）1 期
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in EarlySymptomatic Alzheimer’s Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Gradual and progressive change in memory function reported by participants or informants for = 6 months
- •MMSE score of 22 to 30 (inclusive) at baseline
- •CDR global score of 0.5 to 1.0 (inclusive), with a memory box score =0.5.
- •Meet 18F flortaucipir PET scan (central analysis) criteria
- •Have a study partner who will provide written informed consent to participate
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 14
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 316
排除标准
- •Contraindication to MRI or PET scans
- •Have known allergies to LY3372689, related compounds, or any components of the formulations
研究者
相似试验
进行中（未招募）
1 期
Donanemab in Early Symptomatic Alzheimer’s DiseaseEUCTR2020-000077-25-PLEli Lilly and Company1,800
已完成
2 期
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseAlzheimer's DiseaseJPRN-jRCT2080223944Eli Lilly Japan K.K.360
招募中
1 期
Donanemab in Early Symptomatic Alzheimer’s DiseaseEUCTR2020-000077-25-NLEli Lilly and Company1,736
已完成
3 期
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer*s DiseaseEarly Symptomatic Alzheimer's DiseaseAlzheimersenile psychosisNL-OMON52785Eli Lilly27
进行中（未招募）
2 期
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseAlzheimer DiseaseJPRN-jRCT2031210449Masaki Takeshi330